Evidence-Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorders

2020 ◽  
pp. 283-306
Author(s):  
Xuefeng Zhang ◽  
Thomas R. Kosten
Keyword(s):  
Clinical Trials ◽  
Behavioral Interventions ◽  
Therapeutic Potential ◽  
Supportive Therapy ◽  
Evidence Based ◽  
Methamphetamine Use ◽  
The Us ◽  
Initial Recovery ◽  
Early Phase Clinical Trials ◽  
New Strategies

Cocaine use disorder is one of the important stimulants use disorders worldwide, and amphetamine/methamphetamine misuse is a growing epidemic. There are no pharmacotherapy treatments approved by the US Food and Drug Administration (FDA) available for these illnesses. Numerous treatments based on a variety of strategies from psychotherapy, pharmacotherapy, to neuromodulation have been tested to date. Clinical efficacy of the trialed treatments, including both negative and positive outcomes. are reviewed and discussed in this chapter. In summary, many agents and interventions showed promising therapeutic potential in preclinical and early phase clinical trials but eventually failed in later larger trials. Thus, behavioral interventions and supportive therapy focusing on detoxification, initial recovery, and relapse prevention remain the major therapeutic approach due to lack of targeted treatment. New strategies and models are urgently needed to develop effective treatments for these detrimental disorders.

Current and Emerging Treatments for Methamphetamine-use Disorder

2021 ◽  
Vol 19 ◽  
Author(s):  
Anna Moszczynska
Keyword(s):  
Clinical Trials ◽  
Causes Of Death ◽  
Methamphetamine Use ◽  
Current Prevalence ◽  
The Us ◽  
Emerging Treatments ◽  
History Of ◽  
Behavioral Therapies ◽  
New Treatments ◽  
Methamphetamine Use Disorder

: Almost two decades have passed since the last methamphetamine (METH) abuse epidemic. In recent years, METH abuse in the US has been rapidly increasing and is currently one of the leading causes of death in our country. Available statistical data indicates re-emergence of METH popularity and suggest an impending third epidemic of METH abuse. Alarmingly, there is no FDA- approved medication for METH use disorder (MUD). This disorder is currently treated with behavioral therapies; however, these therapies have limitations and would benefit from the addition of a MUD pharmacotherapy. Unfortunately, clinical trials have not yet found consistently effective pharmacotherapy for MUD. This review outlines the history of METH use, provides information on current prevalence of METH abuse and MUD, describes medications that have been in clinical trials for MUD, and addresses current as well as potential new treatments for MUD.

Diabetes (Children and Adults)

2014 ◽  
Author(s):  
Wendy Auslander ◽  
Elizabeth Budd
Keyword(s):  
Clinical Trials ◽  
Disease Management ◽  
Social Workers ◽  
Psychosocial Functioning ◽  
Behavioral Interventions ◽  
Evidence Based ◽  
Helping Professionals ◽  
Treatment Of Diabetes

The purpose of this article is to provide an overview of: diabetes and its significance, the differences in types of diabetes, and landmark clinical trials that have resulted in changes in philosophy and treatment of diabetes. Second, a review of the various types of evidence-based and promising behavioral interventions in the literature that have targeted children and adults are presented. Social workers and other helping professionals are uniquely positioned to work collaboratively to improve psychosocial functioning, disease management, and prevent or delay complications through behavioral interventions for children and adults with diabetes.

scholarly journals Prostate-Specific Membrane Antigen-Based Therapeutics

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Naveed H. Akhtar ◽  
Orrin Pail ◽  
Ankeeta Saran ◽  
Lauren Tyrell ◽  
Scott T. Tagawa
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Monoclonal Antibodies ◽  
Prostate Specific Membrane Antigen ◽  
Prostate Cell ◽  
Drug Conjugates ◽  
The Us ◽  
External Domain ◽  
Early Phase Clinical Trials ◽  
Specific Membrane

Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to significant morbidity and mortality. While significant therapeutic advances have been made, available systemic therapeutic options are lacking. Prostate-specific membrane antigen (PSMA) is a highly-restricted prostate cell-surface antigen that may be targeted. While initial anti-PSMA monoclonal antibodies were suboptimal, the development of monoclonal antibodies such as J591 which are highly specific for the external domain of PSMA has allowed targeting of viable, intact prostate cancer cells. Radiolabeled J591 has demonstrated accurate and selective tumor targeting, safety, and efficacy. Ongoing studies using anti-PSMA radioimmunotherapy with177Lu-J591 seek to improve the therapeutic profile, select optimal candidates with biomarkers, combine with chemotherapy, and prevent or delay the onset of metastatic disease for men with biochemical relapse. Anti-PSMA monoclonal antibody-drug conjugates have also been developed with completed and ongoing early-phase clinical trials. As PSMA is a selective antigen that is highly overexpressed in prostate cancer, anti-PSMA-based immunotherapy has also been studied and utilized in clinical trials.

scholarly journals Recent advances in treatment of heart failure

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 1475 ◽  
Author(s):  
Takeshi Kitai ◽  
WH Wilson Tang
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
New Drugs ◽  
Significant Progress ◽  
Clinical Endpoints ◽  
Proper Patient Selection ◽  
Treat Heart Failure ◽  
The Us ◽  
Early Phase Clinical Trials ◽  
Study Designs

With the total cases and economic burden of heart failure continuing to rise, there is an overwhelming need for novel therapies. Several drugs for heart failure have succeeded in preclinical and early-phase clinical trials, but most of them failed to show the real benefit in pivotal clinical trials. Meanwhile, the US Food and Drug Administration recently approved two promising new drugs to treat heart failure: ivabradine and sacubitril/valsartan. Furthermore, some of the newer agents in testing offer the potential for significant progress in addition to these drugs. Patiromer and zirconium cyclosilicate are attractive agents that are expected to prevent hyperkalemia during renin-angiotensin-aldosterone system inhibition, and serelaxin and urodilatin are promising drugs in the treatment of acute heart failure. Future clinical trials with more appropriate study designs, optimal clinical endpoints, and proper patient selection are mandatory to assess the true efficacy of these attractive compounds in clinical practice.

Systematic review methodology for development: An example from microfinance

2018 ◽  
Vol 43 (1) ◽  
pp. 65-77 ◽  
Author(s):  
Carina Van Rooyen ◽  
Ruth Stewart ◽  
Thea De Wet
Keyword(s):  
Systematic Review ◽  
International Development ◽  
Health Sector ◽  
Evidence Based ◽  
Systematic Review Methodology ◽  
Development Interventions ◽  
The Us ◽  
Sub Saharan ◽  
The Impact ◽  
Evidence Based Decision Making

Big international development donors such as the UK’s Department for International Development and USAID have recently started using systematic review as a methodology to assess the effectiveness of various development interventions to help them decide what is the ‘best’ intervention to spend money on. Such an approach to evidence-based decision-making has long been practiced in the health sector in the US, UK, and elsewhere but it is relatively new in the development field. In this article we use the case of a systematic review of the impact of microfinance on the poor in sub-Saharan African to indicate how systematic review as a methodology can be used to assess the impact of specific development interventions.

Sign in / Sign up

Export Citation Format

Share Document